1. Patient Questions and Expert Answers in Psoriasis:

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Patient Case 1: Darryl

5. Patient Case 1: Darryl (cont)

6. Diagnostic Workup for PsA

7. Treatment Options for Darryl

8. IL-17 Effect on Structural Disease Progression

9. CV Risk in Patients With Psoriasis

10. Severity of Disease

11. Delphi Consensus of Treatment Targets

12. Patient Case 1: Darryl

13. Patient Case 2: Emily

14. Patient Case 2: Emily (cont)

15. Treatment Options for Emily

16. Secukinumab Efficacy in Palmoplantar Psoriasis (GESTURE Trial)

17. Adverse Events (GESTURE Trial)

18. Patient Case 2: Emily

19. Patient Case 3: Laurie

20. Patient Case 3: Laurie (cont)

21. Treatment Options for Laurie

22. Patient Case 3: Laurie

23. Patient Case 4: Brent

24. Patient Case 4: Brent (cont)

25. Treatment Options for Brent

26. Patient Case 4: Brent

27. Criteria for Systemic Biologic Therapy

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)